Piramal Enterprises Limited - Knowledge, Action, Care

The results of Piramal Industries were announced on 16th May 2016 for the quarter ended 31st March 2016. Hers’s a sneak peek into the numbers

• There was a growth of 34% in Revenues during Q4FY16 standing at 1734 crores
• A massive jump in Operating Profits by 141% for Q4FY16 standing at 468 crores
• Net Profit saw a superb growth of 89% during Q4FY16 and was at 180 crores
• 29% growth in Revenues during FY2016 standing at 6610 crores
• 111% growth in Operating Profits during FY2016 standing at 1872 crores
• 126% growth in Net Profit during FY2016 standing at 951 crores

BUSINESS HIGHLIGHTS FOR THE YEAR

Financial Services

• Loan book saw growth by 174% to 13048 crores as on 31st March 2016 vs 4766 crores as on 31st March 2015
• Alternative AUM was up standing at 8717 crores
• Healthcare

Pharma sollutions

• Multiple reorganizations at world class forum for good performance in quality, reliability and compliance
• Coldstream Acquisition successfully implemented
• Capacity expansion done at Discovery Services & Grange mouth completed

Critical Care

• Market share improvement seen in UK
• Launched co-promotion of two of Cumberland’s branded hospital products in the United States

Consumer products

• Acquisition of Little’s a baby care brand portfolio
• Acquisition of 5 Brands from Organon India & MSD
• Distribution Network expanded to 1500 tons from 481 towns earlier

About The Company

Piramal Enterprises Limited is a diversified company headquartered in Mumbai, and belongs to the Piramal Group. The company has a presence in the pharmaceutical, financial services and information management sectors. The Company has presence in over 100 countries and manufacturing bases in USA, Great Britain, Sri Lanka, China and Canada. In the pharmaceutical space, Piramal Enterprises offer services across the entire drug lifecycle – from development and commercial manufacturing to off-patent supplies of Active Pharmaceutical Ingredients (APIs) and formulations. Piramal Enterprises has well known brands like Saridon, Lacto Calamine, i-Pill and Supractiv. PEL is also engaged in drug discovery & research and has strong pipeline of development products in 4 therapeutic areas: Oncology, Inflammation, Diabetes and Anti-Infectives.

In the financial services space, Piramal Enterprises manages a real estate focused PE fund – Indiareit and an NBFC that is focused on lending to real estate and education sectors. The Company’s information management business, Decision Resources Group is well known a provider of information based services to the healthcare industry.

The company has consistent and strong revenue performance across all business segments resulting in significant growth in operating profits and net profits. The financial services business grew more than 20% in 13 out of last 15 quarters while healthcare grew in 19 out of last 20 quarters. The financial services business has a strong portfolio with total investments, loans and AUM of 24291 crores.

Conclusion:

PIRAMAL ENTERPRISES is one of the Multibagger Shares, identified by Dynamic Research at the end of every month. PIRAMAL ENTERPRISES can be a great investment opportunity which can give you high return. PIRAMAL ENTERPRISES is a well analyzed Multibagger Stock, based on our technical and fundamental research. Piramal Enterprises share price is trading at 1427 with a P/E of 26; market cap for the stock is 24600 crores. The 52 week high / low for the stock is 1536 and 804 respectively. The current ratio is 2.28. Debt equity ratio is 0.56 which is very good. RoE is 24.28 which is also very good; we can buy the stock at its CMP of 1427 adding on dips till 1350 with a target of 1600 for a medium term outlook.

To get more support & resistance of the stock please visit Piramal Enterprises share price forecast.